Floatz logo

Toripalimab

Prostate CA

baotai Liangmonoclonal_antibodyPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Prostate CA cohort.

Asset / SponsorPhaseRating
N-(5-ISOQUINOLINESULFONYL)-1,4-PERHYDRODIAZEPINE
baotai Liang
Phase 2/3B
Fezolinetant
Chinese University of Hong Kong
Phase 2CCC
Fk-Pc101
Cellvax Therapeutics Inc
Phase 2CCC
68Ga-PSMA-CYC
First Affiliated Hospital of Fujian Medical University
Phase 1/2CC

Same molecule, other indications

Toripalimab is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
ToripalimabDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →